Opposite Regulation of Homer Signal at the NMJ Postsynaptic Micro Domain between Slow- and Fast-Twitch Muscles in an Experimentally Induced Autoimmune Myasthenia Gravis (EAMG) Mouse Model - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36499379/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Relevance: In this study, we functionally characterize the novel and brain permeable GHB analog (E)-2-(5-hydroxy-2-phenyl-5,7,8,9-tetrahydro-6H-benzo[7]annulen-6-ylidene)acetic acid (Ph-HTBA).
-
Dr HamidDecember 21, 2022Accelerated postsynaptic remodelling and disturbance of neuromuscular transmission are common features of autoimmune neurodegenerative diseases.
The Polish Headache Society and the Headache Section of the Polish Neurological Society Consensus Statement: update on new pharmacological therapies for migraine in clinical practice and public medication reimbursement program for chronic migraine
Source : https://doi.org/10.5114/aoms/153955
The latest paper concerning the management of migraine in Poland was published in 2021 [ 1] and the previous one (in Polish) in 2019. The Polish recommendations were based on...
Relevance: The Polish recommendations were based on the guidelines of migraine treatment developed by the European Headache Federation (EHF, 2019) and the American Headache Society (AHS) published in 2021. The Polish guidelines took into consideration special Polish conditions and therapeutic options available in Poland, in regard to the Summary of Product Characteristics of the drugs with indication for use in migraine, the evidence-based medicine approach, good clinical practice rules, and the knowledge and experience of the experts of the Polish Headache Society (PHS/PTBG), the Headache Section of the Polish Neurological Society (HSPNS/SBGPTN), and the Polish Pain Society (PPS). It should be underlined that both the EHF and the AHF have also updated the migraine treatment guidelines/statements recently.
Can calcitonin gene-related peptide monoclonal antibody improve migraine and restless legs syndrome?
Source : https://www.jns-journal.com/article/S0022-510X(22)00324-0/fulltext
A significant association between migraine and restless legs syndrome (RLS) has been reported, and their coexistence is not uncommon. We report a patient with concomitant migraine and RLS who showed...
Conclusions: We report a case of improvement of both migraine and RLS after treatment with CGRP monoclonal antibody. Additional studies are needed to clarify how CGRP antagonism affects RLS symptoms in patients with migraine and RLS comorbidity.
-
Huma Sheikh, CEO, NY Neurology Medicine, PCDecember 03, 2022Would be good to know the link.
-
Migraine ConnectOctober 31, 2022Key Points
• Source: Journal of the Neurological Sciences
• Conclusion: “We report a case of improvement of both migraine and RLS [restless legs syndrome] after treatment with CGRP monoclonal antibody. Additional studies are needed to clarify how CGRP antagonism affects RLS symptoms in patients with migraine and RLS comorbidity.”
• In the current case, a 47-year-old woman who has a history of being treated for migraine without aura with dopamine agonists and α2δ ligands experienced recent worsening of migraine and RLS symptoms. She was therefore started on the CGRP monoclonal antibody galcanezumab.
• After 1 month of treatment, the number of headache days reduced from 20 to 4, and her score on the International RLS Study Group Rating Scale improved. Additionally, photo/phono/osmo-phobia improved. This clinical improvement was observed at 5 months.
• The effect of CGRP monoclonal antibody on RLS remains to be elucidated.
Two-year effectiveness of erenumab in resistant chronic migraine: a prospective real-world analysis - The Journal of Headache and Pain
Source : https://thejournalofheadacheandpain.biomedcentral.com/articles/10.1186/s10194-022-01507-8
Background Controlled and real-world evidence have demonstrated the efficacy of calcitonin gene related peptide (CGRP) monoclonal antibodies (MABs) in migraine. However, data on the over-one-year sustained effectiveness of CGRP MABs...
Conclusions: Long-term sustained effectiveness of erenumab was reported only by a minority of resistant CM patients. Although more research in resistant migraine is needed, Erenumab can provide long-term meaningful reduction in migraine load and migraine-related disability in some patients.
-
Huma Sheikh, CEO, NY Neurology Medicine, PCDecember 03, 2022Hope this works in real life patients as well.
Adverse Events Reported with Therapies Targeting the CGRP Pathway During the First 6 Months Post-launch: A Retrospective Analysis Using the FDA Adverse Events Reporting System - Advances in Therapy
Source : https://link.springer.com/article/10.1007/s12325-022-02346-4
Introduction Through 2018, three calcitonin gene-related peptide pathway-targeted monoclonal antibodies (CGRP mAbs) had received US Food and Drug Administration (FDA) approval for migraine prevention: erenumab, fremanezumab, and galcanezumab.
Conclusions: "Conclusion: These results aid in supporting the safety profile of CGRP mAbs in the real-world setting and may provide clinicians and patients with additional insight when considering migraine preventive treatments."
-
Huma Sheikh, CEO, NY Neurology Medicine, PCDecember 03, 2022Good to know.